GSK pulls out of $20 billion race for Pfizer consumer assets

LONDON (Reuters) – GlaxoSmithKline has quit the race to buy Pfizer’s consumer healthcare business, endangering an auction the U.S. drugmaker hoped would bring in as much as $20 billion.

Powered by WPeMatico

Scroll to top